Intravitreal Bevacizumab for Inflammatory Neovascular Membranes

Intravitreal Bevacizumab for the Treatment of Neovascular Membranes in Patients With Intraocular Inflammation

Intravitreal injection of Bevacizumab in patients with Neovascular Membranes secondary to intraocular inflammation. We injected a single injection of Bevacizumab (2.5 mg/0.1 ml) and evaluate visual acuity , Fluorescein angiogram and retinal thickness by Optical Coherence Tomography (OCT) in 4 patients with Vogt Koyanagi Harada disease, 1 patient with Serpiginous Choroidopathy and 1 patient with Multifocal Choroiditis.

Inclusion Criteria:

• Clinical Diagnose
• Patient Consent
• Chronic stage of inflammation

Exclusion Criteria:

• only eye
• age lower than 30 yo.
• Systemic condition